Peter Evan Harwin - 08 Jun 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Director
Issuer ticker: VRDN
Reported as of: 08 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2022, 07:30:14 UTC
Prior SEC filing: 09 Jun 2022
Next SEC filing: 08 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Lara Meisner, Attorney-in-Fact for Peter Evan Harwin

Key filing fact

Peter Evan Harwin filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 10 Jun 2022.

Key facts

This page summarizes Peter Evan Harwin's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2022, 07:30.

Change

Previous filing in this sequence was filed on 09 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRDN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 08 Jun 2022
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $12.31
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board.

Footnote F2

Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.